Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs
Press release
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Analysis Highlights Growth To $32.86 Billion By 2030 At 16.2% CAGR
08-19-2026 12:56 PM CET | Health & Medicine
Press release from: The Business Research Company
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
The market for glucagon-like peptide (GLP)-1 agonists used in weight loss is poised for significant expansion in the coming years. This growth reflects rising global health concerns about obesity and advances in pharmaceutical treatments aimed at managing weight effectively and sustainably. Below, we explore the market size, the key players involved, emerging trends, and the major segments shaping this rapidly evolving sector.
Steady Market Expansion Forecast for GLP-1 Agonists Weight Loss Drugs
The glucagon-like peptide (GLP)-1) agonists weight loss drugs market is projected to reach $32.87 billion by 2030, growing at a robust compound annual growth rate (CAGR) of 16.2%. This upward trajectory is driven by several factors, including the approval of new GLP-1 medications, growth in specialized obesity clinics, broader insurance coverage, a stronger emphasis on long-term weight management, and the increasing prevalence of obesity around the world. Key trends anticipated during this period involve a surge in demand for pharmacological approaches to weight loss, wider use of injectable formulations, expanding adoption of GLP-1 therapies beyond diabetes management, development of obesity treatment programs, and enhancements in patient adherence to extended therapy regimens.
The glucagon-like peptide (glp)-1 agonists weight loss drugs market size has grown rapidly in recent years. It will grow from $15.5 billion in 2025 to $18.02 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to rising obesity prevalence, diabetes drug innovation, lifestyle disease burden, early glp-1 diabetes use, healthcare awareness campaigns.
Download a free sample of the glucagon-like peptide (glp)-1 agonists weight loss drugs market report:https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR
Factors Contributing to Market Growth in GLP-1 Agonists
The rising global obesity rates are a significant catalyst for the GLP-1 agonists market expansion, highlighting the urgent need for effective weight management solutions. Simultaneously, healthcare systems and providers are increasingly focusing on long-term strategies for weight control, which supports sustained demand for these drugs.
Another important driver is the approval of innovative GLP-1 based drugs, which broadens the therapeutic options available to patients. The expansion of obesity-focused clinics and improved insurance policies that cover these treatments also play a crucial role in facilitating access and affordability for a larger patient population.
View the full glucagon-like peptide (glp)-1 agonists weight loss drugs market report:https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-glp-1-agonists-weight-loss-drugs-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR
Key Industry Players Leading the GLP-1 Agonists Weight Loss Drugs Market
Several prominent companies are influential in driving innovation and market growth for GLP-1 agonists in weight loss treatment. Top organizations include Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co Inc., Boehringer Ingelheim, Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc., Roche Holding AG, and Teva Pharmaceutical Industries Ltd.
In a recent significant move, F. Hoffmann-La Roche AG acquired Carmot Therapeutics for $2.7 billion in December 2023. This acquisition grants Roche access to Carmot’s portfolio of incretin-based treatments for obesity and diabetes, including dual GLP-1/GIP receptor agonists CT-388 and CT-868, along with the GLP-1 receptor agonist CT-996. Carmot Therapeutics, based in the US, specializes in developing therapies that modify the course of metabolic diseases like obesity and diabetes.
Emerging Trends in the Global GLP-1 Agonists Weight Loss Drugs Industry
Pharmaceutical companies are actively focusing on creating novel obesity treatment options that enhance drug efficacy and patient outcomes. These therapies work by mimicking the natural GLP-1 hormone to regulate appetite, increase feelings of fullness, and promote weight loss. They contribute to obesity management by improving metabolic functions and supporting sustained weight control over the long term.
For instance, in November 2023, Eli Lilly and Company secured FDA approval for Zepbound, a drug aimed at chronic weight management in adults suffering from obesity or overweight conditions accompanied by related health issues such as type 2 diabetes or sleep apnea. Zepbound functions by activating both GIP and GLP-1 hormone receptors, which helps suppress appetite while boosting metabolic processes.
Detailed Market Segmentation Within the GLP-1 Agonists Weight Loss Drugs Sector
The market for GLP-1 agonists weight loss drugs is broken down into several key categories:
1) Drug Types: Semaglutide, Liraglutide, Tirzepatide, and Other Drugs
2) Routes of Administration: Parenteral and Oral
3) Distribution Channels: Hospital Pharmacies, Retail Pharmacies, and Other Pharmacies
Further subcategories include:
– Semaglutide products: Ozempic, Wegovy, Rybelsus
– Liraglutide products: Saxenda, Victoza
– Tirzepatide products: Mounjaro, Zepbound
– Other drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide
This segmentation provides a comprehensive framework for understanding the diverse offerings and delivery methods available within this marketplace.
Our 2026 market reports now include enhanced strategic insights through:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Analysis Highlights Growth To $32.86 Billion By 2030 At 16.2% CAGR here
News-ID: 4607704 • Views: …
More Releases from The Business Research Company
08-21-2026 | Health & MedicineThe Business Research Company
Micropropagation Market Report 2026 Market Outlook Supported By A Forecast 9% CA …The micropropagation market is gaining significant attention as a vital method for plant multiplication and cultivation. With the growing demand for sustainable agriculture and technological advances, this sector is on track for substantial growth. Let’s explore the market size, emerging players, key trends, and segmentation that define the micropropagation industry today.
Projected Growth and Market Size of the Micropropagation Market
The micropropagation market is set to experience robust expansion over…
08-21-2026 | Health & MedicineThe Business Research Company
Microbiology And Bacterial Culture Media Market Insights Highlight Segment Expan …The microbiology and bacterial culture media market is poised for significant expansion as it continues to play a vital role in healthcare, research, and industrial sectors. With evolving technologies and increasing demand for efficient microbial testing, this market is set to witness substantial growth and innovation by 2030.
Projected Growth and Market Size in the Microbiology and Bacterial Culture Media Market
Forecasts indicate that the microbiology and bacterial culture media…
08-21-2026 | Health & MedicineThe Business Research Company
Microbial Identification Market Report Evaluates Growth Drivers, Challenges And …The microbial identification market is set to experience substantial expansion over the coming years, driven by cutting-edge technological advancements and increasing demand across various industries. With the integration of innovative tools and methodologies, this sector is poised to reach impressive milestones by 2030. Let’s explore the market’s size, key players, emerging trends, and segmentation to gain a clearer understanding of its future prospects.
Market Size and Growth Expectations in the Microbial…
08-21-2026 | Health & MedicineThe Business Research Company
Micro Computed Tomography Market Report Provides Insights Into Market Evolution …The micro computed tomography market is on track for substantial expansion in the coming years, driven by technological advancements and a broadening range of applications. As industries and research fields increasingly embrace this imaging technology, the market is poised for significant growth and innovation through 2030.
Expected Market Size and Growth Trajectory of the Micro Computed Tomography Market
The micro computed tomography market is projected to reach a value of…
More Releases for GLP
02-18-2026 | Health & MedicineABNewswire
GLP-1 SuperDefender: The Revolutionary Oral Protection Appliance Against “Ozempi …Los Angeles, California – Feb 18, 2026 – As medications like Ozempic Registered , Wegovy Registered , and Mounjaro Registered continue to reshape the future of weight management and diabetes treatment, millions of patients are unknowingly facing a growing dental crisis. Reports of acid reflux, dry mouth, and teeth grinding are rising among GLP-1 medication users, leading to irreversible enamel erosion and tooth loss; Collectively known as “Ozempic Teeth”.
In response…
02-17-2026 | Business, Economy, Finances, B …ABNewswire
American Made GLP-1 Names CoreAge Rx As Best GLP-1 Provider for 2026Image: https://www.abnewswire.com/upload/2026/02/8efbd0ec583b0fd3f145d91eb24f2e05.jpg
American Made GLP-1, a US- based healthcare resource dedicated to reviewing and comparing GLP-1 treatment providers, has released its latest rankings of telehealth platforms offering physician-supervised GLP-1 programs for weight management, naming CoreAge Rx as the #1 GLP-1 Provider and awarding the platform an outstanding 4.9 out of 5 rating. The independent review evaluated more than 10 U.S.-based telehealth providers and recognized CoreAge Rx with the designation “Editor’s Choice,”…
01-12-2026 | Associations & OrganizationsGetnews
GLP Diet Review: Tailored Nutrition and Support for GLP-1 UsersImage: https://www.globalnewslines.com/uploads/2026/01/1768225059.jpg
GLP Diet Review – A Personalized GLP-1 Diet
The GLP Diet [https://glp.diet/?utm_source=abnewswire&utm_medium=organic&utm_campaign=bio] is a personalized wellness program designed to help users maximize the benefits of their GLP-1 weight loss medications. It offers tailored meal plans, balanced recipes, guided workouts, lifestyle challenges, and practical tools for tracking progress. Built around each user’s unique needs, it turns complex nutrition advice into clear daily actions that support weight loss, better health, and long-term…
12-17-2025 | SportsABNewswire
Alpharetta Medical Clinic Earns Top Recognition for Excellence in Peptide, GLP-1 …Dr. Weight Loss of Atlanta in Alpharetta is proud to announce its recognition as the top-rated provider of medical weight loss and peptide therapy services in the Alpharetta area. This distinction reflects the clinic’s sustained commitment to clinical excellence, patient-centered care, and successful treatment outcomes in the field of metabolic health.
Alpharetta, GA – December 16, 2025 – Dr. Weight Loss of Atlanta [https://drweightlossofatlanta.com/peptide-therapy-alpharetta] in Alpharetta is proud to announce its…
12-17-2025 | SportsABNewswire
Medical Clinic Recognized as Top Peptide, GLP-1, & GLP-3 Therapies in Sandy Spri …Dr. Weight Loss of Atlanta announced today that its Sandy Springs location has earned recognition as a leading medical weight loss and peptide therapy clinic in Sandy Springs, reflecting exceptional patient satisfaction, consistently strong clinical outcomes, and a reputation for delivering personalized, expert-guided care.
Sandy Springs, GA – December 16, 2025 – Dr. Weight Loss of Atlanta [https://drweightlossofatlanta.com/peptides-sandy-springs] announced today that its Sandy Springs location has earned recognition as a leading…
11-24-2025 | Health & MedicineGlp1-pr
My Start GLP 1 Reviews: The GLP 1 That is Changing the Way America loss WeightIn the modern era of health innovation, few breakthroughs have generated as much excitement as My Start GLP 1. In 2025, it has rapidly become one of the most talked-about doctor-supervised weight loss programs in the United States. With thousands of verified patient success stories, My Start GLP 1 has positioned itself as more than a trend-it is a science-backed revolution changing how we understand metabolism, hunger, and sustainable fat…
© 2004 – 2026 openPR. All rights reserved.
made & hosted in  
FAQ|Imprint|Privacy Policy|Terms & Conditions|Contact Point DSA|Reporting Form DSA|Cookie Settings
